腹腔内注射尿激酶治疗结核性腹膜炎  

Therapy tuberculous peritonitis by intra-abdominal injection urokinase

作　　者：蔡俊岭 

机构地区：[1]河南省驻马店市中心医院传染病科,河南驻马店463000

出　　处：《中国当代医药》2011年第8期46-47,共2页China Modern Medicine

摘　　要：目的:观察和评价腹腔内注入尿激酶治疗结核性腹膜炎的疗效。方法:将86例患者随机分为治疗组和对照组,在常规抗结核药物治疗和腹穿抽液的基础上,治疗组于每次抽液后用尿激酶100000IU加20ml0.9%氯化钠溶液溶解后注入腹腔;对照组注入20ml0.9%氯化钠溶液。治疗结束后比较两组的疗效。结果:治疗组的腹腔积液吸收时间、腹穿次数、腹膜厚度及腹膜粘连发生率均明显低于对照组(P<0.05)。结论:腹腔注射尿激酶治疗结核性腹膜炎可以促进积液吸收、减轻腹膜增厚、粘连,改善患者预后。Objective：To observe and assess the curative effect of tuberculous peritonitis by intra-abdominal injection urokinase.Methods：The 86 patients were randomly divided into urokinase therapy group and control group.After routine applying anti-tuberculosis drugs and tapping the celiac fluid,the therapy group were given 100 000 IU urokinase and 20 ml NS inject celiac,and the control group were given 20 ml NS.Results：The time of celiac effusion absorption,the number of abdomen wearing,the thickness of peritoneal and the incidence of peritoneal adhesion in the treatment group were significantly lower than those in control group（P0.05）.Conclusion：The method of intra-peritoneal injection urokinase to treat tuberculous peritonitis can promote effusion absorption,alleviate peritoneal thickening and adhesion,improve patient outcomes.

关 键 词：尿激酶 腹腔内注入 结核性腹膜炎 

分 类 号：R977.3[医药卫生—药品]